PDCD1 and melanoma: In this study, we employed quantitative multiparameter flow cytometry to assess expression of antigen-presenting molecules MHC-I and MHC-II on melanoma cells in pre-treatment biopsies from patients subsequently receiving anti-PD-1 or combination (anti-PD-1 plus anti-CTLA-4) immunotherapy.